as 04-25-2025 4:00pm EST
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | NEWTOWN |
Market Cap: | 1.7M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 79.0K |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -4.33 | EPS Growth: | N/A |
52 Week Low/High: | $0.26 - $4.69 | Next Earning Date: | 05-12-2025 |
Revenue: | $520,000 | Revenue Growth: | -19.25% |
Revenue Growth (this year): | 0.04% | Revenue Growth (next year): | 75.10% |
HSDT Breaking Stock News: Dive into HSDT Ticker-Specific Updates for Smart Investing
Medical Device Network
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
MT Newswires
3 months ago
GlobeNewswire
3 months ago
MT Newswires
3 months ago
The information presented on this page, "HSDT Helius Medical Technologies Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.